The U.S. Food and Drug Administration has approved the expanded use of Johnson & Johnson's drug Caplyta as an add-on treatment for adults with major depressive disorder, the company said on Thursday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback